As the dominant industrial conversion route, freeze-dried injectable presentation represents the primary downstream use of Classical Swine Fever Vaccine, Live (Tissue Culture Origin) because the finished dose must retain infectivity through lyophilization, storage, and reconstitution under field conditions. The clarified tissue culture harvest is blended with a stabilizer solution in a jacketed stainless steel vessel held at 2–8°C; sucrose and dextran 40 are used as primary glass-forming excipients because their amorphous matrices raise the collapse temperature and protect the viral envelope during primary drying. The blend is filtered through a terminal membrane filter, then filled into siliconized Type I glass vials under ISO Class 5 laminar flow in an isolator. Filling line control follows ISO 13408-1:2008 aseptic processing; fill volume tolerance is typically ±0.1 mL for a 10 mL reconstituted dose. Lyophilization is performed in a shelf freeze dryer with shelf temperature mapped to the formulation collapse temperature, which is determined by freeze-drying microscopy; primary drying shelf setpoints are commonly maintained between −30°C and −20°C for sucrose-stabilized cakes. Chamber pressure is controlled at 60–100 µbar during sublimation, and secondary drying is terminated when the cake temperature reaches 25°C at a residual moisture level not exceeding 2.5% w/w by USP <921> Method 1c. Reconstitution with water for injection or phosphate-buffered saline yields a suspension with brief opalescence; the reconstituted product is not filtered because filtration would remove viral aggregates and reduce titre. Needle-free intradermal administration uses a 0.2 mL dose from a validated applicator; injectable solutions must pass the particulate matter test of Ph. Eur. 2.9.19 after reconstitution. The primary incompatibility is residual humidity: vials exposed to ambient RH above 60% during unloading can rehydrate the cake edge and cause titre collapse. Cold-chain storage at 2–8°C is required; long-term stability at −20°C or −80°C is used for bulk frozen antigen but not for freeze-dried finished doses because repeated freeze-thaw cycles damage the live virus. Batch-to-batch variance in tissue culture harvest titre is controlled by normalizing the pre-lyophilization suspension to a target virus concentration, and the minimum release titre after lyophilization is set in the approved marketing authorization; published data for this specific configuration across all markets is limited.

Why Does Oral Baiting Require a Buffered Liquid Core Rather Than a Dry Powder Blend?

Oral vaccination of wild boar against classical swine fever relies on a liquid suspension core because the enveloped pestivirus loses infectivity rapidly when dried without an amorphous glass-former and when exposed to gastric pH below 4.0. The API is blended at 2–8°C with a buffer composed of 10 mM sodium phosphate, sucrose, and dextran; the target pH is 6.8–7.4, which maintains virus envelope integrity during bait storage and transit. The liquid core is filled into aluminium-sealed blister cavities embedded in a cereal-fat matrix; liquid fill volume is typically between 1.0 mL and 2.5 mL per bait, but the exact volume is specified by the field vaccination license. The filled core is not lyophilized; instead, it is kept at 2–8°C until aerial or manual distribution. A static mixer with low-shear rotor speed of 50–100 rpm is used for blending to avoid mechanical titre loss. Peristaltic filling with silicone tubing is preferred over rotary piston filling because the low shear protects viral particles from cavitation. Seal integrity is tested according to ISO 11607-1:2019; any blister with seal width below 3 mm is rejected because humidity ingress would rehydrate the core and precipitate stabilizer crystals. The bait is designed to release the liquid core in the oral cavity rather than the stomach; tonsillar uptake is the primary route for immune induction, and prolonged gastric residence reduces infectivity. The liquid core is not a conventional feed premix; it is a cold-chain vaccine presentation. Published titre distribution data for C-strain tissue culture origin API in this specific oral core is limited.

In development-level oral delivery work, the tablet and enteric-coated capsule formats for live CSFV tissue culture origin antigen are not pharmacopoeial standard forms. The manufacturing sequence begins with a pre-lyophilized API-sucrose powder that is mixed with mannitol and sodium bicarbonate in a low-shear tumble blender at 3–8 rpm for no more than 10 min; extended blending causes comminution of the lyophilized glass matrix and titre loss. Direct compression is performed at a main compression force not exceeding 8 kN to limit adiabatic heating; higher compression forces densify the matrix and reduce dissolution in the oral cavity. Tablet hardness is controlled to 20–40 N because friable cores release the virus more readily in buccal or tonsillar contact. The compressed core is coated with a pH-sensitive methacrylic acid copolymer dispersion; coating thickness is adjusted so that enteric release initiates at pH above 5.5, not at gastric pH. Capsule formats use hydroxypropyl methylcellulose shells rather than gelatin to avoid moisture exchange with the hygroscopic lyophilisate; capsule filling machines are set to dosator speed below 40 cycles/min and the powder bed is kept at 4–8°C. The pathogen-safety and release criteria follow the same live viral vaccine monograph requirements as injectable forms, but bioequivalence or field efficacy data for oral tablet delivery of classical swine fever virus are limited. The main operational boundary is that the API cannot be wet-granulated with aqueous binder at room temperature; granulation fluid must be a chilled stabilizer solution and tray drying is not used because temperatures above 37°C denature the viral envelope. If a capsule or tablet formulation fails the dissolution test in phosphate buffer pH 6.8 per Ph. Eur. 2.9.3, the batch is not reworked because additional milling would reduce infectivity.

Powder, Granule, and Premix Handling in Cold-Chain Aseptic Filling

For powder and granule handling, the live CSFV tissue culture origin antigen is first converted to a lyophilized powder with a residual moisture not exceeding 2.5% w/w; this powder is then milled through a 500 µm stainless steel screen under a nitrogen blanket to avoid static charge and humidity uptake. The milled lyophilisate is blended with sorbitol or sucrose granules in a vertical bin blender; batch size is limited to 20 L because larger powder beds develop internal temperature gradients. The powder is discharged into low-density polyethylene sachets through a screw feeder operating at 5–10 rpm; filled sachet weight tolerance is ±2% and seam strength is tested according to ISO 11607-1:2019. A premix of API-sucrose powder with 1:9 w/w sodium bicarbonate carrier is used in some oral bait manufacturing lines; this premix is not a medicated feed premix because live virus is not stable in feed pellets and the oral vaccination route requires direct mucosal contact. The premix is stored at −20°C and used within 24 h after thawing at 2–8°C. Granulation for tablet compression is limited to dry granulation by slugging or roller compaction at roll pressure below 20 kN/cm; wet granulation introduces enthalpy and moisture that destabilize the live virus. Aseptic powder handling suites operate at ISO Class 7 background with ISO Class 5 local filling, as required by ISO 13408-1:2008. Residual water content is measured by USP <921> and oxygen headspace is kept below 2% v/v in sealed sachets. Batch-to-batch variance in powder flow is controlled by adding 0.5% w/w fumed silica as a glidant; higher fumed silica levels accelerate viral adsorption to the silica surface and reduce recoverable titre.

At 2–8°C, the tissue culture origin CSFV API can be maintained as a frozen bulk suspension or as a refrigerated liquid with stabilizer, but the half-life in dilute phosphate buffer at 25°C is less than 24 h. Liquid filling is performed in a jacketed vessel at 4–8°C using a diaphragm pump with low shear impeller; the liquid is then dispensed into Type I glass vials or laminated polyethylene-aluminium sachets. The formulation for solution dosage contains sucrose at 5% w/v, dextran 40 at 2% w/v, and sodium phosphate buffer at 10 mM pH 7.2 ± 0.2. This liquid is not suitable for prolonged storage at ambient temperature; cold-chain break at 30°C for 2 h reduces infectivity by more than 1 log10 TCID50, although published data for this specific configuration is limited. Viscosity is maintained below 10 mPa·s at 5°C to allow needle-free jet injection or direct oral drenching. Particulate matter after final filling is tested according to Ph. Eur. 2.9.19; subvisible particles in the size range 10–25 µm must be within monograph limits. The liquid formulation is not autoclaved after virus addition; all components except the live virus are pre-sterilized by moist heat or membrane filtration. Sterility is verified by direct inoculation into media according to Ph. Eur. 2.6.1. The primary incompatibility is air: continuous nitrogen sparging of the liquid mixing vessel maintains dissolved oxygen below 0.5 mg/L to reduce oxidative damage to the viral envelope. This liquid solution is not interchangeable with the freeze-dried product because stabilizer concentrations are lower and the titre degrades faster; the choice between solution and lyophilisate depends on the target dose volume, route, and cold-chain window.

When a Premix Is Required for Oral Bait Manufacture, Cold-Chain Dilution Becomes the Critical Control

This premix route exists where a bait manufacturer receives lyophilized API and must dilute it into a flowing blend for subsequent filling into blister cores or sachets. The premix is prepared at 2–8°C in a stainless steel V-blender with a chilled jacket; the lyophilized API is first suspended in a 1:4 w/w carrier of chilled sorbitol and sucrose. The suspension is then mixed with sodium bicarbonate to a final buffer capacity of 20 mM at pH 7.0 ± 0.2. The target titre per gram of premix is determined by the field campaign dose, not by a feed assay; the premix is not intended for direct ingestion as a dry powder because the moisture in saliva would not uniformly suspend the virus. Instead, the premix is metered into a liquid core filling line within 30 min of mixing. Temperature excursion above 8°C during transfer is monitored with calibrated data loggers at 1 min intervals; any segment exceeding 10°C for more than 5 min triggers batch rejection because titre decay follows first-order kinetics. The premix is not dried after wetting; drying would subject the virus to air-water interface stress and freeze-drying without a new stabilizer would not restore titre. The V-blender speed is restricted to 10–15 rpm and total blend time to 5 min; higher shear forces break the lyophilized glass matrix and expose the virus to osmotic stress. Cleaning validation between batches follows current ICH Q7 requirements for biological APIs because residual live virus particles can cross-contaminate subsequent non-viral veterinary products. The premix is not a feed additive and should not be top-dressed onto solid feed; the oral bait route has a different exposure window and different mucosal target than conventional medicated feed.

Dual-Chamber Vial Filling of Lyophilised API and Diluent Requires Partitioned Stability Data

Dual-chamber vials contain the lyophilized live CSFV tissue culture origin antigen in one compartment and water for injection or buffer in the other, separated by a pharmaceutical-grade butyl rubber stopper with a bypass channel. Filling the API chamber follows the same aseptic lyophilization cycle as single-chamber vials, but the primary drying cycle is extended by 10–15% because the vial geometry changes heat transfer; the cake thickness in the bottom chamber is limited to 3 mm to maintain uniform sublimation. The diluent chamber is filled aseptically after autoclaving of the vial system; the filled diluent volume is matched to the reconstitution volume specified in the marketing authorization. Moisture transfer across the chamber barrier must be controlled because butyl rubber has finite water vapour transmission; vials are packaged with a desiccant and tested for cake moisture at release and at 6-month stability intervals. The delivery sequence during injection requires the user to press the plunger, displacing diluent through the bypass into the API chamber; the device must produce a reconstituted suspension without foaming. Foaming is a product quality defect because it introduces air-water interface stress and reduces viral titre. The primary standard for container closure integrity is USP <1207>; a vacuum decay method is used to detect microleaks that would allow ingress of humidity or escape of the live virus aerosol. The dual-chamber format is used where field personnel must avoid separate diluent vials and syringe transfer; it reduces preparation error but increases manufacturing cost. Published data for dual-chamber CSFV live vaccine stability is limited, so each assembled configuration requires separate cold-chain stability studies under the target field storage profile.